Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.57 |
| ▸ | MAPT | P10636 | 4/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.57 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.57 |
| ▸ | RAD51 | Q06609 | 2/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.49 |
| ▸ | NQO2 | P16083 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12927928 | 0.85 | MAPT (0.56) | ALDH1A1MAPTHSD17B10CYP1A2RAB9A | |
| SCHEMBL30318924 | 0.85 | MAPT (0.56) | ALDH1A1MAPTHSD17B10CYP1A2RAB9A | |
| SCHEMBL11415313 | 0.84 | ALDH1A1 (0.55) | ALDH1A1MAPTMEN1CYP3A4ALOX15 | |
| SCHEMBL11863066 | 0.83 | ALDH1A1 (0.57) | ALDH1A1MAPTMEN1CYP3A4ALOX15 | |
| SCHEMBL11864377 | 0.83 | NPSR1 (0.55) | ALDH1A1MAPTMEN1CYP3A4ALOX15 | |
| SCHEMBL14836990 | 0.80 | TGM2 (0.55) | ALDH1A1MAPTMEN1CYP3A4ALOX15 | |
| SCHEMBL10494616 | 0.80 | MAPT (0.72) | ALDH1A1MAPTKMT2AHSD17B10CYP1A2 | |
| SCHEMBL10494613 | 0.80 | MAPT (0.72) | ALDH1A1MAPTKMT2AHSD17B10CYP1A2 | |
| SCHEMBL3804765 | 0.80 | RAB9A (0.56) | ALDH1A1MAPTMEN1CYP3A4KMT2A | |
| SCHEMBL12130854 | 0.80 | ALDH1A1 (0.59) | ALDH1A1MAPTMEN1KMT2AHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0448188-A2 | Process and intermediates for the preparation of substituted 6-(3,5,6,7-tetrahydropyrrolo-[2,1-c][1,2,4]-thiadiazol-3-ylidenimino)-7-fluoro-2H-1,4-benzoxazin-3(4H)-ones | SCHERING AKTIENGESELLSCHAFT (DE) | 1991-09-25 | — | — | EP | claimed |
| EP-2578584-B1 | ARYLAMINO PURINE DERIVATIVES, PREPARATION METHOD AND PHARMACEUTICAL USE THEREOF | SI CHUAN UNIV (CN) | 2020-08-12 | — | — | EP | disclosed |
| US-9096601-B2 | Arylamino purine derivatives, preparation method and pharmaceutical use thereof | CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO., LTD. (CN) | 2015-08-04 | — | — | US | disclosed |
| US-20130203986-A1 | Arylamino Purine Derivatives, Preparation Method and Pharmaceutical Use Thereof | SI Chuaan University (CN) | 2013-08-08 | — | — | US | disclosed |
| EP-2578584-A1 | ARYLAMINO PURINE DERIVATIVES, PREPARATION METHOD AND PHARMACEUTICAL USE THEREOF | Si Chuan University (CN) | 2013-04-10 | — | — | EP | disclosed |
| EP-0882717-B1 | NITROGENOUS HETEROCYCLIC COMPOUNDS | KYOWA HAKKO KIRIN CO LTD (JP) | 2010-09-08 | — | — | EP | disclosed |
| US-6750218-B2 | INHIBITORY ACTIVITY ON PHOSPHORYLATION OF PLATELET-DERIVED GROWTH FACTOR (PDGF) RECEPTOR USEFUL FOR THE TREATMENT OF CELL-PROLIFERATIVE DISEASES SUCH AS ARTERIOSCLEROSIS, VASCULAR REOBSTRUCTION, CANCER AND GLOMERULOSCLEROSIS | MILLENNIUMIUM PHARMACEUTICALS, INC. | 2004-06-15 | — | — | US | disclosed |
| US-20030229077-A1 | Nitrogen-containing heterocyclic compounds | MATSUNO KENJI (JP) | 2003-12-11 | — | — | US | disclosed |
| US-6472391-B2 | INHIBIT PHOSPHORYLATION OF PDGF RECEPTOR TO HINDER ABNORMAL CELL GROWTH AND CELL WANDERING; TREATMENT OF CELL-PROLIFERATIVE DISEASES SUCH AS ARTERIOSCLEROSIS, VASCULAR REOBSTRUCTION, CANCER AND GLOMERULOSCLEROSIS. | MILLENNIUM PHARMACEUTICALS, INC. | 2002-10-29 | — | — | US | disclosed |
| US-20020068734-A1 | Nitrogen-containing heterocyclic compounds | MILLENNIUM PHARMACEUTICALS, INC. | 2002-06-06 | — | — | US | disclosed |
| US-6207667-B1 | USEFUL FOR THE TREATMENT OF CELL-PROLIFERATIVE DISEASES SUCH AS ARTERIOSCLEROSIS, VASCULAR REOBSTRUCTION, CANCER AND GLOMERULOSCLEROSIS | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2001-03-27 | — | — | US | disclosed |
| US-6169088-B1 | FOR THE PREVENTION OR TREATMENT OF CELL-PROLIFERATIVE DISEASES SUCH AS ARTERIOSCLEROSIS, VASCULAR REOBSTRUCTION, CANCER AND GLOMERULOSCLEROSIS | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2001-01-02 | — | — | US | disclosed |
| US-6074813-A | SILVER HALIDE PHOTOSENSITIVE MATERIAL FOR EMULSION LAYERS | FUJI PHOTO FILM, CO., LTD. (JP) | 2000-06-13 | — | — | US | disclosed |
| EP-0882717-A1 | NITROGENOUS HETEROCYCLIC COMPOUNDS | KYOWA HAKKO KOGYO KABUSHIKI KAISHA (JP) | 1998-12-09 | — | — | EP | disclosed |
| EP-0426112-B1 | Silver halide photographic material | FUJI PHOTO FILM CO LTD (JP) | 1996-02-28 | — | — | EP | disclosed |
| US-5151357-A | Light sensitive elements with phosphonate groups | FUJI PHOTO FILM CO., LTD. (JP) | 1992-09-29 | — | — | US | disclosed |
| EP-0448188-A2 | Process and intermediates for the preparation of substituted 6-(3,5,6,7-tetrahydropyrrolo-[2,1-c][1,2,4]-thiadiazol-3-ylidenimino)-7-fluoro-2H-1,4-benzoxazin-3(4H)-ones | SCHERING AKTIENGESELLSCHAFT (DE) | 1991-09-25 | — | — | EP | disclosed |
| EP-0448188-A2 | Process and intermediates for the preparation of substituted 6-(3,5,6,7-tetrahydropyrrolo-[2,1-c][1,2,4]-thiadiazol-3-ylidenimino)-7-fluoro-2H-1,4-benzoxazin-3(4H)-ones | SCHERING AKTIENGESELLSCHAFT (DE) | 1991-09-25 | — | — | EP | disclosed |
| EP-0426112-A1 | Silver halide photographic material | FUJI PHOTO FILM CO., LTD. (JP) | 1991-05-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030229077-A1 | Nitrogen-containing heterocyclic compounds | ERBB4, NPR1, PDGFRB | ALDH1A1 3252/4885MAPT 4833/4885MEN1 4594/4885 |
| US-20020068734-A1 | Nitrogen-containing heterocyclic compounds | PDGFRB, MKI67, PDGFRA | ALDH1A1 3314/4885MAPT 4830/4885MEN1 4677/4885 |
| US-20130203986-A1 | Arylamino Purine Derivatives, Preparation Method and Pharmaceutical Use Thereof | EGFR, PNP, GART | ALDH1A1 886/4885MAPT 4808/4885MEN1 4327/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.